Lb Pharmaceuticals Inc. announced it raised $969,000 in an initial filing from an offering of $1 Million

Company

Location

About

LB Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of schizophrenia. Our lead drug candidate is a second-generation antipsychotic and a potential first-in-class benzamide to enter the U.S. market. With robust clinical development underway and a focus on long-term patient outcomes, we aim to set a new standard of care for neuropsychiatric conditions.